Failure to achieve CR after initial induction therapy in AML is an adverse prognostic factor; therefore, the presence of t(8;21)/RUNX1::RUNX1T1 with three-way translocations may warrant consideration of hematopoietic stem cell transplantation at an earlier stage in the treatment course. The gene discussed is RUNX1; the disease is acute myeloid leukemia.